Intervacc AB (publ) (FRA:2E9)

Market Cap	28.11M +380.4%
Revenue (ttm)	1.91M +127.1%
Net Income	-5.73M
EPS	-0.02
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	1
Open	0.0318
Previous Close	0.1118
Day's Range	0.0318 - 0.0318
52-Week Range	0.0232 - 0.1118
Beta	n/a
RSI	47.79
Earnings Date	Feb 17, 2026

About Intervacc AB

Intervacc AB (publ) develops novel veterinary vaccines for animals in Sweden. The company’s product pipeline includes Stangvac, a vaccine against equine strangles for horses; INV274, antigens for a vaccine against streptococcus suis for the treatment of weaned piglets; and INV412, a multi-component vaccine to protect against several bacteria which cause mastitis for treating cows. It also engages in marketing and distribution of veterinary products in the Nordic markets, which includes vaccines and pharmaceuticals for swine, horses, cattle, and...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1983
• Employees: 15
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 2E9

Financial Performance

In 2024, Intervacc AB's revenue was 11.79 million, an increase of 46.84% compared to the previous year's 8.03 million. Losses were -75.52 million, -26.58% less than in 2023.

Financial numbers in SEK